We are live on ! Find out more
HEPA

Hepion Pharmaceuticals
HEPA

Delisted

HEPA was delisted on the 12th of May, 2025.

Back to rankings

37 hedge funds and large institutions have $11.9M invested in Hepion Pharmaceuticals in 2021 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 7 increasing their positions, 14 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

274% more call options, than puts

Call options by funds: $1.53M | Put options by funds: $409K

14% less funds holding

Funds holding: 43 → 37 (-6)

44% less capital invested

Capital invested by funds: $21.3M → $11.9M (-$9.36M)

50% less first-time investments, than exits

New positions opened: 5 | Existing positions closed: 10

50% less repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 14

Holders
37
Holders Change
-6
Holders Change %
-13.95%
% of All Funds
0.65%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
7
Reduced
14
Closed
10
Calls
$1.53M
Puts
$409K
Net Calls
+$1.12M
Net Calls Change
+$1.08M

Top Buyers

Rank Fund Capital Flow
1
Bank of New York Mellon
Bank of New York Mellon
New York
+$72K
2
AMC
Asset Management Corp
Illinois
+$67.2K
3
PNC Financial Services Group
PNC Financial Services Group
Pennsylvania
+$62.4K
4
Bank of America
Bank of America
North Carolina
+$49.6K
5
HF
HRT Financial
New York
+$40K

Top Sellers

Rank Fund Capital Flow
1
IC
Ikarian Capital
Texas
-$1.3M
2
Two Sigma Advisers
Two Sigma Advisers
New York
-$1.2M
3
ACM
Altium Capital Management
New York
-$883K
4
Two Sigma Investments
Two Sigma Investments
New York
-$485K
5
VF
Virtu Financial
New York
-$225K

HEPA Hedge Fund Activity: Q3 2021 in Review

37 of the 5,728 institutional investors tracked by Wall St. Rank reported a position in Hepion Pharmaceuticals (HEPA) for Q3 2021, worth a combined $11.9M — down 44% from $21.3M a quarter earlier.

Sellers outnumbered buyers: 10 funds closed out of HEPA and 5 opened new positions — a net loss of 5 holders — while 14 trimmed existing stakes and 7 added.

The largest buyer was Bank of New York Mellon, adding an estimated $72K. The largest seller was Ikarian Capital, cutting an estimated $1.3M.

  • 37 institutional investors held Hepion Pharmaceuticals (HEPA) as of Q3 2021, down from 43 in Q2 2021.
  • Funds reported $11.9M of Hepion Pharmaceuticals stock for Q3 2021, down 44% quarter-over-quarter.
  • 5 funds opened new Hepion Pharmaceuticals positions in Q3 2021 and 10 closed out, a net change of -5 holders.
  • The largest Hepion Pharmaceuticals buyer in Q3 2021 was Bank of New York Mellon, an estimated $72K added.
  • The largest Hepion Pharmaceuticals seller in Q3 2021 was Ikarian Capital, an estimated $1.3M sold.

Based on aggregated 13F filings for Q3 2021.